Published in Nat Rev Drug Discov on January 01, 2009
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Autophagy and the integrated stress response. Mol Cell (2010) 11.21
Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol (2010) 9.06
Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A (2011) 6.30
The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer (2012) 3.75
G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov (2011) 3.31
Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol (2010) 3.30
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell (2012) 3.00
Toll-like receptor-4 inhibits enterocyte proliferation via impaired beta-catenin signaling in necrotizing enterocolitis. Gastroenterology (2009) 2.64
MicroRNAs in NF-kappaB signaling. J Mol Cell Biol (2011) 2.50
C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature (2014) 2.44
The IKK complex contributes to the induction of autophagy. EMBO J (2009) 2.41
FoxM1 is a general target for proteasome inhibitors. PLoS One (2009) 2.34
Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov (2013) 2.31
Survivin and IAP proteins in cell-death mechanisms. Biochem J (2010) 2.18
Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Natl Acad Sci U S A (2010) 2.17
IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep (2009) 2.14
A20: from ubiquitin editing to tumour suppression. Nat Rev Cancer (2010) 2.08
The multifaceted role of MTDH/AEG-1 in cancer progression. Clin Cancer Res (2009) 1.89
Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat Cell Biol (2012) 1.87
The molecular pathology of cancer. Nat Rev Clin Oncol (2010) 1.86
The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets (2010) 1.85
Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin (2013) 1.83
Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J Exp Med (2009) 1.80
BAG3: a multifaceted protein that regulates major cell pathways. Cell Death Dis (2011) 1.77
Chronic inflammation induces telomere dysfunction and accelerates ageing in mice. Nat Commun (2014) 1.72
Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res (2010) 1.48
A new target for proteasome inhibitors: FoxM1. Expert Opin Investig Drugs (2010) 1.48
Emerging roles for the non-canonical IKKs in cancer. Oncogene (2010) 1.48
Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines. Proc Natl Acad Sci U S A (2011) 1.48
Apoptosis and molecular targeting therapy in cancer. Biomed Res Int (2014) 1.47
Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov (2011) 1.46
miR-29b defines the pro-/anti-proliferative effects of S100A7 in breast cancer. Mol Cancer (2015) 1.46
Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA. Oncogene (2013) 1.44
Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J Clin Invest (2011) 1.41
Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network. Proc Natl Acad Sci U S A (2012) 1.37
Of the atypical PKCs, Par-4 and p62: recent understandings of the biology and pathology of a PB1-dominated complex. Cell Death Differ (2009) 1.35
Anticancer and cancer chemopreventive potential of grape seed extract and other grape-based products. J Nutr (2009) 1.33
Conditional deletion of IkappaB-kinase-beta accelerates helicobacter-dependent gastric apoptosis, proliferation, and preneoplasia. Gastroenterology (2009) 1.31
Conditional ablation of Ikkb inhibits melanoma tumor development in mice. J Clin Invest (2010) 1.28
Regulation of Akt signaling activation by ubiquitination. Cell Cycle (2010) 1.28
IL-1β-driven neutrophilia preserves antibacterial defense in the absence of the kinase IKKβ. Nat Immunol (2010) 1.27
OTULIN restricts Met1-linked ubiquitination to control innate immune signaling. Mol Cell (2013) 1.25
Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res (2009) 1.25
Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb) (2011) 1.22
TRAP-1, the mitochondrial Hsp90. Biochim Biophys Acta (2011) 1.22
NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front Biosci (Landmark Ed) (2011) 1.19
Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions. Immunol Rev (2011) 1.18
Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage. Retrovirology (2009) 1.17
Inhibition of autophagy by TAB2 and TAB3. EMBO J (2011) 1.15
A critical role for the NFkB pathway in multiple myeloma. Oncotarget (2010) 1.15
FAS-associated factor 1 (FAF1): diverse functions and implications for oncogenesis. Cell Cycle (2009) 1.15
Retracted Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway. J Biol Chem (2010) 1.14
Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat Commun (2015) 1.13
Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFĸB pathway. Cell Cycle (2011) 1.11
Inhibition of NF-kappa B activity in mammary epithelium increases tumor latency and decreases tumor burden. Oncogene (2010) 1.09
Aberrant regulation of FBW7 in cancer. Oncotarget (2014) 1.08
The two faces of FBW7 in cancer drug resistance. Bioessays (2011) 1.08
Cell-selective inhibition of NF-κB signaling improves therapeutic index in a melanoma chemotherapy model. Cancer Discov (2011) 1.08
G-protein coupled receptor kinase 5 mediates lipopolysaccharide-induced NFκB activation in primary macrophages and modulates inflammation in vivo in mice. J Cell Physiol (2011) 1.07
Protandim, a fundamentally new antioxidant approach in chemoprevention using mouse two-stage skin carcinogenesis as a model. PLoS One (2009) 1.07
Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia. Gastroenterology (2013) 1.07
A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. Hepatology (2010) 1.06
Nanodrug delivery in reversing multidrug resistance in cancer cells. Front Pharmacol (2014) 1.05
Curcumin enhances the efficacy of chemotherapy by tailoring p65NFκB-p300 cross-talk in favor of p53-p300 in breast cancer. J Biol Chem (2011) 1.04
Post-formulation peptide drug loading of nanostructures for metered control of NF-κB signaling. Biomaterials (2011) 1.04
Parthenolide, a sesquiterpene lactone, expresses multiple anti-cancer and anti-inflammatory activities. Inflammation (2012) 1.04
Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth. Oncogene (2012) 1.04
Sesquiterpenoids lactones: benefits to plants and people. Int J Mol Sci (2013) 1.03
IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals. Oncogene (2011) 1.03
Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis. Clin Cancer Res (2014) 1.03
The role of Rac1 in the regulation of NF-κB activity, cell proliferation, and cell migration in non-small cell lung carcinoma. Cancer Biol Ther (2012) 1.02
The complex interplay between autophagy and NF-κB signaling pathways in cancer cells. Am J Cancer Res (2011) 1.01
Macrophage autophagy in atherosclerosis. Mediators Inflamm (2013) 1.00
Paradoxic effects of metformin on endothelial cells and angiogenesis. Carcinogenesis (2014) 1.00
Ectodysplasin regulates hormone-independent mammary ductal morphogenesis via NF-κB. Proc Natl Acad Sci U S A (2012) 0.99
Nuclear factor-kappaB (NF-kappaB) is a novel positive transcriptional regulator of the oncogenic Wip1 phosphatase. J Biol Chem (2009) 0.99
Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens. Haematologica (2011) 0.99
New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. Nutr Cancer (2011) 0.98
α-catenin acts as a tumour suppressor in E-cadherin-negative basal-like breast cancer by inhibiting NF-κB signalling. Nat Cell Biol (2014) 0.98
Bcl2-associated athanogene 3 interactome analysis reveals a new role in modulating proteasome activity. Mol Cell Proteomics (2013) 0.98
Diet-induced obesity increases NF-kappaB signaling in reporter mice. Genes Nutr (2009) 0.98
Epigenetic modulating agents as a new therapeutic approach in multiple myeloma. Cancers (Basel) (2013) 0.97
Inhibition of CRM1-mediated nuclear export of transcription factors by leukemogenic NUP98 fusion proteins. J Biol Chem (2010) 0.97
The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. Br J Haematol (2010) 0.97
Human papillomavirus type 16 E6 and E 7 proteins alter NF-kB in cultured cervical epithelial cells and inhibition of NF-kB promotes cell growth and immortalization. Virology (2012) 0.97
Pathogenetic mechanisms in gastric cancer. World J Gastroenterol (2014) 0.97
IKKα represses a network of inflammation and proliferation pathways and elevates c-Myc antagonists and differentiation in a dose-dependent manner in the skin. Cell Death Differ (2011) 0.96
Nerve growth factor in cancer cell death and survival. Cancers (Basel) (2011) 0.96
IκBKβ and NFκB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry. Carcinogenesis (2012) 0.95
IKKβ regulates the repair of DNA double-strand breaks induced by ionizing radiation in MCF-7 breast cancer cells. PLoS One (2011) 0.95
microRNA-146a inhibits G protein-coupled receptor-mediated activation of NF-κB by targeting CARD10 and COPS8 in gastric cancer. Mol Cancer (2012) 0.95
Cancer: A tumour gene's fatal flaws. Nature (2009) 0.94
Minireview: modulation of hormone receptor signaling by dietary anticancer indoles. Mol Endocrinol (2009) 0.94
Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner. Cancer Cell (2016) 0.94
Regulation of ubiquitination-mediated protein degradation by survival kinases in cancer. Front Oncol (2012) 0.93
Triptolide avoids cisplatin resistance and induces apoptosis via the reactive oxygen species/nuclear factor-κB pathway in SKOV3(PT) platinum-resistant human ovarian cancer cells. Oncol Lett (2013) 0.93
Requirement of nuclear factor κB for Smac mimetic-mediated sensitization of pancreatic carcinoma cells for gemcitabine-induced apoptosis. Neoplasia (2011) 0.93
Beyond NF-κB activation: nuclear functions of IκB kinase α. J Biomed Sci (2013) 0.93
BLT2 up-regulates interleukin-8 production and promotes the invasiveness of breast cancer cells. PLoS One (2012) 0.92
The hallmarks of cancer. Cell (2000) 113.05
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol (1998) 21.48
Nuclear factor-kappaB in cancer development and progression. Nature (2006) 18.31
Missing pieces in the NF-kappaB puzzle. Cell (2002) 17.83
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14
NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol (2005) 13.98
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell (2000) 11.90
NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science (1998) 11.70
The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol (2004) 10.85
Multiple myeloma. N Engl J Med (2004) 10.81
Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06
Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell (2000) 8.69
A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest (2007) 8.54
IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell (2007) 8.48
Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res (2003) 7.86
IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell (2007) 7.74
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell (1995) 7.18
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res (2001) 6.93
Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol (2001) 6.73
MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature (1997) 6.53
The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov (2004) 6.21
A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell (1994) 5.94
NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell (2001) 5.88
The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity (2002) 5.38
Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science (2000) 5.22
BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol (2002) 5.09
A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science (2004) 4.95
NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem (2002) 4.94
NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell (2007) 4.56
Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene (2006) 4.53
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol (2008) 4.33
IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature (2005) 4.31
From signatures to models: understanding cancer using microarrays. Nat Genet (2005) 4.29
IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest (2005) 4.07
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood (2002) 3.73
Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer (2005) 3.72
IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol (2005) 3.68
TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature (2002) 3.48
Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature (2002) 3.40
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem (2004) 3.35
CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J (2002) 3.30
Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kappa b-inducing kinase. Nat Genet (1999) 3.17
The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis (2007) 3.16
Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell (2004) 3.14
Two pathways to NF-kappaB. Mol Cell (2002) 3.12
Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. Science (2001) 3.11
TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity (2008) 3.03
Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science (2008) 2.99
Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood (1996) 2.98
STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med (2002) 2.90
The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. Proc Natl Acad Sci U S A (1996) 2.62
Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene (2006) 2.60
Posttranscriptional downregulation of c-IAP2 by the ubiquitin protein ligase c-IAP1 in vivo. Mol Cell Biol (2005) 2.57
TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol (2004) 2.51
Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood (2007) 2.46
The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol (2006) 2.31
Rescue of TRAF3-null mice by p100 NF-kappa B deficiency. J Exp Med (2006) 2.17
The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene (2001) 2.04
Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival. Mol Cell Biol (2006) 2.04
Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase. Immunity (2004) 1.99
RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation: critical roles for p100. J Biol Chem (2003) 1.96
B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol (2004) 1.93
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood (2002) 1.92
New drugs for myeloma. Oncologist (2007) 1.84
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res (2006) 1.75
Specificity of TRAF3 in its negative regulation of the noncanonical NF-kappa B pathway. J Biol Chem (2006) 1.75
Abnormal immune function of hemopoietic cells from alymphoplasia (aly) mice, a natural strain with mutant NF-kappa B-inducing kinase. J Immunol (2000) 1.70
Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem (2001) 1.63
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood (2006) 1.56
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol (2008) 1.52
Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene (2003) 1.44
The anti-death machinery in IKK/NF-kappaB signaling. J Clin Immunol (2005) 1.27
Cytokines and signal transduction. Best Pract Res Clin Haematol (2005) 1.25
Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol (2001) 1.22
Immunodeficiency of alymphoplasia mice (aly/aly) in vivo: structural defect of secondary lymphoid organs and functional B cell defect. Eur J Immunol (2000) 1.19
Dying for NF-kappaB? Control of cell death by transcriptional regulation of the apoptotic machinery. Curr Opin Cell Biol (2003) 1.18
Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth. Br J Haematol (2007) 1.17
The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol (2007) 1.13
Disease-specific genomic analysis: identifying the signature of pathologic biology. Bioinformatics (2007) 1.12
Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol (2004) 1.11
Molecular diagnosis of lymphoid malignancies by gene expression profiling. Curr Opin Hematol (2002) 1.10
Nuclear factor kB as a target for new drug development in myeloid malignancies. Haematologica (2007) 1.05
Growth inhibition of multiple myeloma cells by a novel IkappaB kinase inhibitor. Clin Cancer Res (2005) 1.05
Deregulated NF-kappaB activity in haematological malignancies. Biochem Pharmacol (2006) 1.04
Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood (2003) 1.04
Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas. Breast Cancer Res (2007) 1.01
State of the art therapy in multiple myeloma and future perspectives. Eur J Cancer (2006) 0.95
Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia (2004) 0.93
Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents. Semin Oncol (2006) 0.86
Immunity, inflammation, and cancer. Cell (2010) 28.27
Missing pieces in the NF-kappaB puzzle. Cell (2002) 17.83
A central role for JNK in obesity and insulin resistance. Nature (2002) 17.27
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91
IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med (2005) 12.07
Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol (2009) 11.76
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol (2004) 10.85
AP-1 as a regulator of cell life and death. Nat Cell Biol (2002) 10.10
Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell (2005) 9.16
Regulation and function of IKK and IKK-related kinases. Sci STKE (2006) 8.98
IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell (2005) 8.78
A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest (2007) 8.54
Intracellular pattern recognition receptors in the host response. Nature (2006) 8.04
Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 8.04
p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell (2008) 6.88
Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell (2008) 6.83
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature (2009) 6.67
Inflammation and colon cancer. Gastroenterology (2010) 6.32
Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol (2011) 6.17
NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature (2008) 6.13
Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature (2005) 5.72
The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity (2002) 5.38
JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab (2007) 5.38
Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science (2005) 5.25
The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell (2006) 5.18
NF-κB and the link between inflammation and cancer. Immunol Rev (2012) 4.74
Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature (2007) 4.68
NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev (2008) 4.61
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57
NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell (2007) 4.56
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature (2012) 4.41
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol (2008) 4.33
IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature (2005) 4.31
An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell (2011) 4.29
Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science (2002) 4.26
NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res (2010) 4.10
Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev (2009) 4.10
IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest (2005) 4.07
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature (2007) 4.00
Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell (2004) 3.98
Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell (2004) 3.94
Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science (2010) 3.86
The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med (2003) 3.85
A KH domain RNA binding protein, KSRP, promotes ARE-directed mRNA turnover by recruiting the degradation machinery. Mol Cell (2004) 3.71
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med (2008) 3.68
Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science (2004) 3.66
Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell (2008) 3.58
Redundant pathways for negative feedback regulation of bile acid production. Dev Cell (2002) 3.51
The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell (2008) 3.35
Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A (2006) 3.33
Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J (2004) 3.32
A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc Natl Acad Sci U S A (2008) 3.27
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature (2010) 3.24
The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature (2004) 3.18
IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. Immunity (2003) 3.12
Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell (2013) 3.08
Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci U S A (2006) 3.02
Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest (2007) 2.99
Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science (2008) 2.99
Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell (2008) 2.98
Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell (2010) 2.89
Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis (2011) 2.74
Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology (2008) 2.70
A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell (2009) 2.64
Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis--CREB and NF-kappaB as key regulators. Immunity (2005) 2.56
Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol (2005) 2.56
Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat Immunol (2009) 2.52
Activation of the E3 ubiquitin ligase Itch through a phosphorylation-induced conformational change. Proc Natl Acad Sci U S A (2006) 2.49
Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res (2010) 2.48
Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity (2010) 2.47
JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins. Dev Cell (2003) 2.45
Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell (2010) 2.43
The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett (2004) 2.41
p38-dependent phosphorylation of the mRNA decay-promoting factor KSRP controls the stability of select myogenic transcripts. Mol Cell (2005) 2.38
Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev (2009) 2.35
Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity (2006) 2.33
Anthrolysin O and other gram-positive cytolysins are toll-like receptor 4 agonists. J Exp Med (2004) 2.32
Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. Proc Natl Acad Sci U S A (2010) 2.32
p63 induces key target genes required for epidermal morphogenesis. Proc Natl Acad Sci U S A (2007) 2.31
Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci U S A (2008) 2.26
CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV Response. Mol Cell (2003) 2.23
I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med (2005) 2.21
IkappaB kinase-alpha acts in the epidermis to control skeletal and craniofacial morphogenesis. Nature (2004) 2.21
Activation of liver X receptors and retinoid X receptors prevents bacterial-induced macrophage apoptosis. Proc Natl Acad Sci U S A (2004) 2.18
Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum (2009) 2.16
A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology (2012) 2.15
Evidence that reactive oxygen species do not mediate NF-kappaB activation. EMBO J (2003) 2.13
IkappaB-kinasebeta-dependent NF-kappaB activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci U S A (2004) 2.12
IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci U S A (2007) 2.09
Obesity, inflammation, and liver cancer. J Hepatol (2011) 2.09
NF-kappaB in cancer: a marked target. Semin Cancer Biol (2003) 2.08
Expanding TRAF function: TRAF3 as a tri-faced immune regulator. Nat Rev Immunol (2011) 2.04
The control of cell motility and epithelial morphogenesis by Jun kinases. Trends Cell Biol (2004) 1.99
IKK beta is required for peripheral B cell survival and proliferation. J Immunol (2003) 1.92
The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell (2011) 1.92
Crystal structure of inhibitor of κB kinase β. Nature (2011) 1.92
Targeting of TAK1 by the NF-kappa B protein Relish regulates the JNK-mediated immune response in Drosophila. Genes Dev (2004) 1.91
Opposing functions of IKKbeta during acute and chronic intestinal inflammation. Proc Natl Acad Sci U S A (2008) 1.90